How do cell therapy companies actually make money?

What actually counts as making money in cell therapy?

Cell therapy companies currently make money in four real ways: selling therapies, sharing product profits, collecting royalties and milestones, or manufacturing therapies for other companies.

Those models look similar from far away, but the economics are completely different. A company selling its own therapy keeps the most upside but also pays for manufacturing, treatment-center support, reimbursement work, sales teams and the next generation of clinical trials. A company with a profit-sharing partner gives away part of the economics but also shares much of that burden. A royalty company can stay much leaner, while a contract manufacturer gets paid without having to invent a successful drug at all.

We should also separate revenue from profit. Iovance's latest quarter is a good example. The company generated about $99 million of product revenue and a 56% gross margin from its cell therapy business, yet it still lost $47 million because R&D, selling costs and the rest of the organization consumed more than the gross profit. CRISPR Therapeutics is even more unusual: Vertex books CASGEVY sales, while CRISPR receives its 40% share of the program economics through the collaboration.

So when we ask whether cell therapy companies make money, the useful question is how much economic value ultimately reaches the company after manufacturing and commercialization costs, rather than how large the therapy's list price looks.

Can a cell therapy really become a billion-dollar business?

Yes. Cell therapy can already support multi-billion-dollar annual franchises, and the latest sales numbers make that hard to dispute.

CARVYKTI generated about $657 million of net trade sales in its latest quarter, 50% more than a year earlier. That quarterly run rate is above $2.6 billion if simply annualized. Breyanzi produced another $484 million in the same quarter, up 41%. Yescarta remains a very large product despite declining sales, with $346 million in the quarter.

Cell therapy used to have a strange commercial profile: enormous theoretical revenue per patient, but too few patients actually getting treated to create large franchises. We now have several therapies doing hundreds of millions of dollars every three months.

The evidence goes beyond revenue. Legend Biotech reported $57.7 million of operating income and $33.2 million of net income in its latest quarter, compared with an operating loss a year earlier. Higher CARVYKTI gross profit was the main reason. A standalone cell therapy company has now shown that a scaled CAR-T franchise can carry a substantial commercial and research organization.

That still describes the winners, not the typical cell therapy company. The gap between the top few products and almost everything else remains huge.

If you want more recent data on this point, please see our latest cell therapy market report.

Why can a $500,000 cell therapy still lose money?

A $500,000 cell therapy can lose plenty of money because the headline price tells us almost nothing about what is left after manufacturing the treatment and running the company.

A 2026 analysis by Health Management, Policy & Innovation using Micromedex Red Book data put 2025 U.S. wholesale acquisition costs at roughly $504,000 for Yescarta, $531,000 for Breyanzi, $528,000 for Abecma and $555,000 for CARVYKTI. Kymriah was close to $594,000. Those are list prices, before discounts and rebates, and they exclude the wider cost of hospital care.

The manufacturer then has to produce an unusually complicated medicine. With an autologous therapy, cells leave one specific patient, travel through a controlled supply chain, enter a manufacturing process, pass quality testing and return to the same patient. A failed batch can mean losing both the production cost and the sale. Factories also carry expensive clean rooms, quality systems and specialist staff whether they are running at full capacity or half empty.

Iovance shows how quickly the apparently huge economics shrink. Its latest quarter brought in about $99 million of product revenue. Cost of sales was approximately $44 million, leaving around $56 million before R&D, sales, administration and depreciation. The company spent roughly $59 million on R&D and another $39 million on selling and administration in the same three months.

A high price per infusion gives cell therapy companies room to build an attractive business. It doesn't do the job for them.

Does cell therapy manufacturing get cheaper at scale?

Yes, and lately we have started to see the cost curve change dramatically once commercial volumes rise.

AUCATZYL gives us one of the cleanest examples. Autolus had negative gross margins in every quarter of 2025. Gross margin improved to 6% in the first quarter of 2026 and then jumped to 55% in the next quarter. At the same time, quarterly product revenue increased from $26.2 million to $45.7 million.

Autolus said the improvement came from lower manufacturing cost per batch as volumes increased, operational efficiency and fewer inventory reserves and write-offs. Cost of sales actually fell to $20.5 million from $24.4 million a year earlier even though product revenue more than doubled. That's real manufacturing leverage.

We see something similar at Iovance. Product revenue reached roughly $99 million in its latest quarter, 66% above the year-earlier period, while gross margin climbed to 56%. Management specifically pointed to higher Amtagvi volumes and more mature internal manufacturing.

The change can be very nonlinear. A cell therapy plant carries a large fixed infrastructure before volumes arrive. Filling that infrastructure with more patient batches can push the cost of each treatment down quickly. Autolus's move from negative margins to 55% in a relatively short period shows why early launch economics can badly understate what a mature franchise may eventually earn.

Are cell therapy sales already dominated by a few winners?

Very much so. The current cell therapy market is much more concentrated than the number of approved products makes it look.

We added up the latest comparable quarterly sales disclosed for eight commercial cell therapies: CARVYKTI, Breyanzi, Yescarta, Tecartus, Amtagvi, CASGEVY, AUCATZYL and Ryoncil. Together they generated about $1.81 billion. The three biggest products alone, CARVYKTI, Breyanzi and Yescarta, contributed roughly $1.49 billion, or 82% of that selected group.

This is not a complete estimate of the global cell therapy market because some approved products do not have clean stand-alone quarterly disclosures. It still gives a useful picture of where the money sits. Approval numbers can make the industry look broad; commercial revenue is much narrower.

The concentration also shows why cell therapy investing is so unforgiving. Moving from zero to an approved product is a huge scientific achievement, but the financial prize disproportionately goes to therapies that become default choices in large treatment settings and can be manufactured at high volume.

Cell therapy	Latest disclosed quarterly sales	Recent direction
CARVYKTI	~$657M	+50% year over year
Breyanzi	$484M	+41% year over year
Yescarta	$346M	-12% year over year
Amtagvi	~$91M U.S. revenue	Strong sequential growth
CASGEVY	~$76M	+151% year over year
Tecartus	$70M	-24% year over year
AUCATZYL	$45.7M	+119% year over year
Ryoncil	~$36M	First full commercial year

If you want more recent data on this point, please see our latest cell therapy market report.

Why is Breyanzi growing while Yescarta is shrinking?

Breyanzi is taking part in a growing CAR-T market while Yescarta is currently losing ground inside it. Cell therapy revenue does not automatically rise with the category.

Bristol Myers Squibb reported $484 million of Breyanzi revenue in its latest quarter, up 41% year over year, and said higher demand was the main driver. Breyanzi has steadily moved into more lymphoma and leukemia settings, giving the commercial network more patients who can potentially receive the same underlying therapy.

Gilead's latest numbers went the other way. Yescarta revenue fell 12% to $346 million and Tecartus fell 24% to $70 million. Gilead explicitly blamed both in-class and out-of-class competition. Total Gilead cell therapy sales declined 14%.

The whole category is not simply moving upward together. Physicians are choosing between CAR-T products, bispecific antibodies and other treatments, while label position, safety, efficacy and ease of treatment keep changing.

A cell therapy company therefore needs more than regulatory exclusivity and a high price. It needs a product that keeps winning actual treatment decisions after competitors arrive.

Does FDA approval mean a cell therapy company has a real business?

No. FDA approval gives a cell therapy company permission to sell; it does not guarantee enough time, cash or patients to survive the commercial ramp.

Adaptimmune is the clearest warning. TECELRA became the first engineered T-cell therapy approved for synovial sarcoma, and early sales were genuinely improving. The company reported $11.1 million of quarterly TECELRA revenue during its launch, more than 150% above the previous quarter, while manufacturing success had reached 100% for commercial patients.

The company still ran out of room. Adaptimmune had only about $26 million of cash at the end of that period and had burned more than $100 million from operations during the first half of the year. It ultimately sold TECELRA and several related cell therapy assets to US WorldMeds for $55 million upfront plus up to $30 million of future payments.

The problem was timing. A personalized cell therapy can need years of research investment, followed by a launch period in which revenue remains too small to cover a fully built manufacturing and commercial organization. A scientifically successful company can reach approval and still arrive there with the wrong balance sheet.

Cash runway deserves nearly as much attention as the approval itself in this sector.

Is partnering with Big Pharma better than selling cell therapy alone?

For many small cell therapy companies, yes. Keeping a large share of a successful therapy while letting a bigger company carry much of the global commercial burden can be a better business than insisting on owning everything.

Legend Biotech's arrangement with Johnson & Johnson is the strongest example we have today. Janssen originally paid Legend $350 million upfront for the collaboration around what became CARVYKTI. Outside Greater China, the companies broadly share costs and profits 50/50, while Legend keeps a larger share in Greater China.

Legend does not book the majority of worldwide CARVYKTI product sales directly. Instead, its latest quarter included $326 million of collaboration revenue from the Janssen relationship. That structure has allowed a company that was once essentially built around one program to participate heavily in a global blockbuster without having to reproduce Johnson & Johnson's entire worldwide commercial organization.

CRISPR Therapeutics made a similar choice with Vertex. Vertex leads CASGEVY's worldwide development, manufacturing and commercialization while CRISPR keeps 40% of program profits and costs. CASGEVY revenue has now reached about $76 million in the latest quarter and is growing quickly.

A partnership becomes unattractive when the biotech gives away nearly all of the upside. The best deals do something harder: they transfer a large amount of execution risk while leaving the original developer with enough economics to become very valuable if the therapy wins.

Cell therapy	Smaller developer	Larger partner	Economics kept by developer
CARVYKTI	Legend Biotech	Johnson & Johnson	Roughly 50% profit/loss outside Greater China; higher share in Greater China
CASGEVY	CRISPR Therapeutics	Vertex	40% of program profit/loss
Anito-cel before acquisition	Arcellx	Gilead/Kite	50% U.S. profit share plus ex-U.S. royalties

Is a cell therapy profit share better than a royalty?

When a therapy becomes a major commercial success, a large profit share can be worth vastly more than an ordinary royalty, and Gilead just put a very large price on that difference.

Before Gilead acquired Arcellx, the two companies were developing anito-cel under a deal that split U.S. profits 50/50 while giving Arcellx royalties outside the United States. The therapy had not yet launched commercially.

Gilead then bought Arcellx at an implied equity value of about $7.8 billion. In announcing the deal, Gilead specifically said full ownership would eliminate the future profit-share, milestone and royalty obligations attached to anito-cel. The agreement also included an extra $5 per-share contingent payment if anito-cel reaches at least $6 billion of cumulative global sales through 2029.

It's an unusually revealing transaction. A 5% royalty on $2 billion of annual sales produces $100 million. A 50% share of a highly profitable $2 billion franchise can produce several times that amount. The profit-share owner also carries far more cost and launch risk, but once a therapy looks likely to succeed, the retained percentage becomes an extremely valuable asset.

Gilead effectively decided that buying the whole company was preferable to continuing to hand half of the U.S. economics to its partner.

If you want more recent data on this point, please see our latest cell therapy market report.

How do cell therapy companies make money before FDA approval?

Pre-commercial cell therapy companies can bring in enormous amounts of cash by selling access to technology and future product rights long before the first commercial patient is treated.

The most striking recent example comes from in vivo CAR-T. Sail Biomedicines announced a collaboration with Johnson & Johnson under which Sail is due to receive initial payments valued at $785 million, including a $465 million equity investment and development-linked payments, while Johnson & Johnson obtained an exclusive option to acquire Sail for another $2.58 billion.

The amount says plenty about how the economics of cell therapy are shifting. Big Pharma is willing to pay heavily before commercial proof when a platform could remove one of the industry's biggest problems: taking cells out of a patient, manufacturing them elsewhere and sending them back. In vivo CAR-T aims to create the engineered cells directly inside the body.

More conventional deals use the same basic structure on a smaller scale: upfront cash, research funding, clinical milestones, regulatory milestones, commercial milestones and eventual royalties. Those payments can fund a biotech for years.

We would still treat this differently from a mature business. An upfront payment can be enormous but happens once. Milestones arrive only if specific events occur. The durable business appears later, when the company has enough products or licensing relationships to make those payments repeat, or when commercial royalties begin.

Can hospitals and insurers choke off cell therapy revenue?

Absolutely. Cell therapy can have physician demand and regulatory approval while still losing potential patients to reimbursement and treatment-center friction.

The U.S. payment system shows why. CMS currently bundles the preparatory procedures required to collect patient-specific cells or tissue into the payment for the autologous cell or gene therapy product. Hospitals therefore have to manage more than an infusion: they coordinate procurement, conditioning, specialist care, billing and sometimes serious toxicity management.

The FDA has already removed one layer of friction. It eliminated the special REMS programs for the established CD19- and BCMA-directed autologous CAR-T therapies after deciding those restrictions were no longer needed. Hospitals no longer have to meet the same special certification requirements that originally came with products such as Yescarta, Breyanzi and CARVYKTI.

CASGEVY shows the international version of the same challenge. The therapy is approved in 39 countries and its eligible population has recently expanded further, yet quarterly revenue is still around $76 million. That is strong growth from a young launch, but far below what a naïve calculation based on eligible patients multiplied by a seven-figure treatment price would suggest.

The commercial patient pool is always smaller than the medically eligible population. A patient has to be diagnosed, referred, insured, accepted by a qualified center, healthy enough for treatment, successfully manufactured for and ultimately infused before a company gets its sale.

Is manufacturing capacity basically a sales limit for cell therapy?

For personalized cell therapy, yes. A company can have more patient demand than revenue simply because it cannot manufacture enough treatments quickly and reliably.

The manufacturing success rate makes the relationship easy to see. Earlier this year, Legend reported that CARVYKTI manufacturing success had reached 99%, more than 95% of orders were being released on time, and turnaround time was falling. The therapy is now available through 348 sites in 19 markets.

Those operational numbers deserve as much attention as prescriptions. With an ordinary pill, demand can usually rise much faster than manufacturing becomes a bottleneck. An autologous CAR-T order creates a unique manufacturing job tied to one patient. If a factory can process 20% more successful batches, that can translate into roughly 20% more potential treatments before other bottlenecks intervene.

Iovance faces the same problem in solid tumors. Amtagvi is now available through more than 95 authorized treatment centers, and the company says its manufacturing process can serve thousands of patients annually. Current turnaround is 31 days or less. Reducing that time means patients can reach treatment sooner and each unit of factory capacity can potentially process more cycles.

As we saw with AUCATZYL's margins, manufacturing scale affects both sides of the income statement. More successful batches create more revenue while spreading the production infrastructure over more treatments.

Will off-the-shelf cell therapy have better economics?

Probably, but today the economic case for off-the-shelf cell therapy is stronger than the commercial proof.

The logic is straightforward. Autologous therapies start with cells collected from each individual patient. An allogeneic product can start with donor cells and potentially generate inventory for many patients. That should make production more standardized, reduce waiting times and spread factory costs over far more doses.

Ryoncil already gives us a commercial example outside CAR-T. Mesoblast reported a 93% product gross margin during the first half of its fiscal year, excluding amortization, while Ryoncil revenue went on to reach approximately $115 million in its first full commercial year. Those margins are far above the early commercial margins we have seen from personalized AUCATZYL and Amtagvi.

The FDA has also recently approved Tregzi from Orca Bio, the first regulatory T-cell-based immunotherapy used with matched-donor hematopoietic stem-cell transplantation. That does not prove a mass-market off-the-shelf CAR-T model, but it widens the set of commercially approved donor-cell approaches.

The biggest cell therapy franchises are still autologous. CAR-T leaders have shown they can generate billions of dollars despite bespoke manufacturing, while broadly scalable allogeneic CAR-T has yet to produce a comparable commercial winner.

So we would give off-the-shelf cell therapy a clear theoretical economic advantage and only a partial commercial victory for now.

If you want more recent data on this point, please see our latest cell therapy market report.

Can cell therapy manufacturers make money without owning a drug?

Yes. Manufacturing cell therapies for other companies is becoming a real business model of its own, and it avoids much of the winner-takes-most clinical risk faced by drug developers.

Cellares offers the clearest example of what this can look like. Bristol Myers Squibb signed a worldwide capacity reservation and supply agreement worth up to $380 million in upfront and milestone payments to move selected CAR-T programs onto Cellares's automated manufacturing platform.

More recently, Kyverna Therapeutics signed a commercial manufacturing and supply agreement with ElevateBio for miv-cel, its autologous CAR-T program for autoimmune diseases. The companies had already spent several years working together on clinical manufacturing, and the new agreement is designed to cover potential U.S. commercial supply as well as global clinical programs.

Lonza is the scaled incumbent version. Its Cell & Gene operations sit inside the company's Specialized Modalities segment, where revenue comes mainly from long-term development and manufacturing agreements. Lonza does not separately disclose a pure cell-therapy margin, so we should not pretend its broader segment economics belong entirely to cell therapy.

The appeal here is diversification. A CDMO can manufacture programs for several customers, meaning one failed clinical trial does less damage to the entire business. The trade-off is obvious too: the manufacturer earns contracted economics rather than owning a therapy that might become a $3 billion franchise.

Business model	Who pays the company?	What the company is really selling	Main economic trade-off
Own therapy	Hospitals / payers	The treatment itself	Highest upside, highest risk
Profit-share partnership	Commercial partner / franchise	A retained share of product economics	Large upside with shared control
Licensing / royalties	Pharma partner	IP and future rights	Lower cost, less upside
Contract manufacturing	Cell therapy developers	Development and production capacity	Diversified revenue, limited blockbuster upside

What kills cell therapy profitability even when sales are growing?

The biggest threat to cell therapy profitability is a company building its cost base faster than its product can generate gross profit.

Autolus currently makes that visible in one income statement. AUCATZYL produced $45.7 million of quarterly revenue and a healthy 55% gross margin, leaving roughly $25 million of gross profit. Autolus still spent about $28 million on R&D and $41 million on selling and administration, producing a $43.8 million operating loss. The company has since cut roughly 13% of its workforce and arranged a credit facility of up to $250 million.

Iovance is further along commercially and faces the same arithmetic at a bigger scale. Its latest quarter brought roughly $99 million of revenue and $56 million of gross profit before depreciation, but R&D and selling costs alone approached $100 million. The company still lost $47 million.

Those companies may eventually grow into their cost structures. What we can already say is that cell therapy needs surprisingly high revenue before a standalone developer looks financially comfortable. A company may have a successful launch, improving gross margins and strong clinical data at the same time and still need fresh financing.

This is also why the partnership model can work so well. Sharing a blockbuster hurts when the product succeeds, but carrying hundreds of millions of dollars of annual infrastructure while waiting for that success can hurt much more.

So how do cell therapy companies actually make money?

Cell therapy companies make durable money by getting enough patients through a difficult treatment and manufacturing system while keeping a large enough share of the economics; today, direct product sales and meaningful profit-sharing partnerships are the two strongest models.

The direct-sales model has the greatest upside. A successful therapy can generate hundreds of thousands of dollars of revenue from a single treated patient, and recent results show that manufacturing margins can improve sharply as volumes grow. The catch is that companies must fund factories, quality systems, treatment-center networks, reimbursement work, sales teams and ongoing R&D for years before that scale arrives.

Profit-sharing partnerships look particularly strong for smaller developers. They let a biotech keep enough exposure to a blockbuster to transform the company while a larger partner contributes manufacturing, global market access and commercialization. The current economics around Legend and CRISPR show how valuable a 40% or 50% retained share can become. Gilead's $7.8 billion acquisition of Arcellx gives us another clue: once an attractive cell therapy gets close to market, eliminating somebody else's profit share can be worth billions.

Royalties, milestones and licensing payments are excellent ways to monetize science earlier and finance development, especially for companies with several programs. Manufacturing companies can build a different kind of business by selling capacity across many cell therapy developers. Neither model normally captures as much value as owning a large share of a commercial winner.

The numbers point to one practical conclusion. Cell therapy is already a real business, but the high price per treatment can be deceptive. The companies making the best money are the ones that turn scientific success into repeatable patient throughput: more referrals, more treatment centers, reliable manufacturing, shorter turnaround times, good reimbursement and lower production cost per batch. Once those pieces line up, a cell therapy can become an unusually valuable pharmaceutical franchise. Until they do, even an approved $500,000 treatment can remain a very expensive company to run.

If you want more recent data on this point, please see our latest cell therapy market report.